AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Cytoplasmic dynein 1 intermediate chain 2

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q13409

UPID:

DC1I2_HUMAN

Alternative names:

Cytoplasmic dynein intermediate chain 2; Dynein intermediate chain 2, cytosolic

Alternative UPACC:

Q13409; B7ZA04; D3DPD4; D3DPD5; D3DPD6; Q32LY9; Q53S84; Q5BJF8; Q7Z4X1; Q96NG7; Q96S87; Q9BXZ5; Q9NT58

Background:

Cytoplasmic dynein 1 intermediate chain 2, also known as Dynein intermediate chain 2, cytosolic, plays a crucial role in the cytoplasmic dynein 1 complex. This protein is essential for the retrograde motility of vesicles and organelles along microtubules, facilitating processes such as membrane transport to the Golgi apparatus, late endosomes, and lysosomes. Its interaction with the dynactin complex through the p150-glued component is vital for dynein function.

Therapeutic significance:

The protein is linked to a neurodevelopmental disorder characterized by microcephaly and structural brain anomalies, highlighting its importance in brain development. Understanding the role of Cytoplasmic dynein 1 intermediate chain 2 could open doors to potential therapeutic strategies for treating such neurodevelopmental disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.